Nelistotug Biosimilar - Research Grade

Human

CD96

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD96 (3.3) In Vivo Antibody - Low Endotoxin (ICH1209)

https://www.imgt.org/mAb-DB/

ICH3002

P40200

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of the anti-CD96 antibody nelistotug, built around the human CD96 (TACTILE) target and provided for research use only. It is not the clinical drug and is not intended for human or veterinary use. Supplied as a human IgG1/kappa format molecule, it is useful as a reference or benchmarking reagent when studying the CD96/CD155 (PVR) axis and the broader CD226/TIGIT/CD96 immune-checkpoint network. Typical research applications include in-vitro CD96 binding and ligand-blocking assays, competition and epitope studies, flow-cytometry staining of CD96-expressing NK and T cells, use as an isotype-matched positive control, and antibody- or ADC-development workflows. Manufactured at research grade with low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and available in bulk milligram-to-gram quantities to support screening, assay standardization, and preclinical model work. Because it is a biosimilar of a human-target antibody rather than the therapeutic itself, all data generated with it are intended for laboratory characterization only. CD96 (also called TACTILE; UniProt P40200) is an immunoglobulin-superfamily transmembrane receptor expressed mainly on NK cells and T cells. It shares the ligand CD155 (PVR/NECL-5) with the activating receptor CD226 (DNAM-1) and the inhibitory receptor TIGIT, and these three receptors form a competitive regulatory network analogous to the CD28/CTLA-4 system. CD96 engagement of CD155 generally delivers inhibitory or dampening signals that limit NK-cell cytotoxicity and cytokine (notably IFN-gamma) production, and CD96 can compete with CD226 for ligand. Because CD155 is frequently upregulated on tumor cells, the CD96/CD155 interaction is studied as an immune-checkpoint mechanism of tumor immune evasion. Blocking CD96 is investigated as a strategy to restore NK- and T-cell antitumor activity, often in combination with PD-1 or TIGIT pathway modulation.

Cell surface antigen CD96, T cell-activated increased late expression protein, T-cell surface protein tactile

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Nelistotug biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Nelistotug biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nelistotug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Nelistotug that binds CD96; for research use only.